Invited speakers

Name: Dr. Emanuela Corsini, PhD
Employer: University of Milan, Italy

1993 – PhD in Food and Environmental Toxicology, Università degli Studi di Milano, Italy.
1987 – Bachelor degree in Food Science and Technology, Università degli Studi di Milano, Italy
1982 – Scientific liceum high school degree

Work experience:
2004 – to present Associate professor of Toxicology at the School of Pharmacy
July – August 1995, visiting scientist Laboratory of Dermatology directed by Dr S. Feldman, Wake Forest University, Winston Salem, NC, USA
November 1994 – March 1995, visiting scientist Laboratory of Immunotoxicology directed by Prof. I. Kimber, CTL, Alderley Park, UK
1989 – 1992, visiting scientist, Laboratory of Toxicology directed by Dr M.I. Luster, NIEHS, RTP, NC, USA

Experience: She is active in training undergraduate and graduate students and in research. Her research focuses on the refinement of alternative in vitro tests for immunotoxicity, and on the understanding at the molecular level the mechanism of action of immunotoxic/immunomodulatory compounds. She has authored over 170 research publications in the area of toxicology. She is active in numerous scientific and professional organizations, serves on several editorial boards of toxicology journals. From 1999-2005 she served as Treasures of the Association for in vitro Toxicology; from 2009-2013 she was Member of EUROTOX Education Sub Committee, from 2005-2011 she was the Chair of the Immunotoxicology and Chemical Specialty Section at EUROTOX; from 2010-2016 she was member of the IUTOX Executive Committee; from 2013 she is member of the EUROTOX Executive Committee; 2019 President of Immunotoxicology Specialty Section at SOT, 2017-2019 member of the Award Committee at SOT, from 2019 she serves as Secretary General of IUTOX.

Name: Nicole C. Kleinstreuer, Ph.D.

Dr. Nicole Kleinstreuer is the acting director of the NTP Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM), leading domestic and international efforts to develop novel testing and analysis strategies that provide more rapid, mechanistic, and human-relevant predictions of potential environmental chemical hazards. She has a secondary appointment in the NIEHS Division of Intramural Research Biostatistics and Computational Biology Branch, and adjunct faculty positions in the Yale School of Public Health and the Eshelman School of Pharmacy at UNC-CH. Kleinstreuer’s research focuses on mathematical and computational modeling of biological systems and their susceptibility to perturbations that result in adverse health outcomes. She is the recipient of numerous prestigious awards including the 2019 Society of Toxicology Achievement Award.

Tim Allen is a Research Associate at the MRC Toxicology Unit, University of Cambridge. He completed his PhD in 2016 on Molecular Initiating Events (MIEs) and how computational methods can be used to predict them in the group of Professor Jonathan Goodman at the Department of Chemistry in Cambridge. Since then he has undertaken post-doctoral work in the Department of Chemistry in Cambridge and at the United States Environmental Protection Agency in North Carolina. This has included work using quantum chemistry density functional theory calculations to predict the mutagenicity of alpha-beta unsaturated carbonyls and understand their reactions with DNA, using 3D Quantitative Structure Activity Relationships to quantitatively predict MIEs and explore the chemical-biological interactions in several cases, and developing in-house computational tools for use by his industrial partners at Unilever’s Safety and Environmental Assurance Centre for use in safety decision making. Tim has also served as a member of ILSI Europe’s expert group on the application of Adverse Outcome Pathways (AOPs) in food ingredient risk assessment and has presented his research at over 20 national and international conferences. In 2019 Tim moved to the MRC Toxicology Unit to continue his work in predictive toxicology, including new investigations into how we can use and understand state-of-the-art machine learning approaches such as deep learning neural networks.

Dr. Knudsen is a Developmental Systems Biologist at the US EPA National Center for Computational Toxicology and Exposure, where he is a lead in the Virtual Tissue Models project. His research on prenatal developmental toxicity and systems biology has led to over 150 scientific papers. Current research is focused on building and testing a ‘virtual embryo’ framework for predictive modeling of developmental toxicity. This entails integration of in-vitro data from HTS (high-throughput screening) profiling in ToxCast/Tox21 with biological knowledge of in-vivo embryology and in-silico cell agent based models for synthetic reconstructing morphogenesis, leading to a quantitative prediction of chemical dysmorphogenesis. Dr. Knudsen is a Past-President of the Teratology Society, Former Editor-in-Chief of Reproductive Toxicology, currently serves as Editor-in-Chief of Current Research in Toxicology.

Peter Loskill is Assistant Professor for Experimental Regenerative Medicine at Eberhard Karls University Tübingen and Organ-on-a-Chip Attract Group Leader at the Fraunhofer IGB in Stuttgart, Germany. Dr. Loskill graduated from Saarland University with a PhD in Physics and spent three years as a postdoctoral fellow / project leader at UC Berkeley developing Organ-on-a-chip (OoC) systems based on human iPS-cells. In 2015, he was named as one of Technology Review’s “Innovators under 35 Germany” and awarded a Fraunhofer ATTRACT Grant. His µOrgano lab ( combines approaches from engineering, biology, physics and medicine to generate next-generation tissue models recapitulating complex human biology in vitro. To advance European OoC research, he coordinates the MSCA-ITN EUROoC (, is part of the EUROoC conference ( organizing committee, and serves as vice-chair of the European OoC-Society (EUROoCS;

Christian Pellevoisin, PhD
Scientific Director, EPISKIN – France

Involved for several years in development and promotion of in vitro toxicology assays based on reconstructed human tissues.
After a PhD in neuroscience at the French National Institute of Health and Medical Research (INSERM) he held a temporary teaching position at the university of Tours (France). He joined L’Oréal R&I in 2000 at the Life Science Research Center where he was involved in development and implementation of computerized tools for alternative to animal approaches in toxicology (results database, expert systems).
In 2004 he was appointed to scientific communication on alternative methods to animal testing and tissue engineering.
In 2011 he joined EPISKIN, a subsidiary of L’Oréal, dedicated to development and production of reconstructed human epithelia. As Scientific Director, he participated to several projects that resulted in the introduction of new models and methods to the market. He developed the EPISKIN Academy program to support through education the use of non animal methods (NAMs) for safety assessment of chemicals, cosmetics, medical devices and to relay EPISKIN commitments to 3Rs.
Engaged for several years in biocompatibility of medical devices he is the Chairman of the French AFNOR S92J commission and convenior of the WG8 skin irritation and sensitization of the ISO/TC194 for biocompatibility of medical devices. He is also L’Oreal R&I Research associate and member of the advisory council of the Indian Society for Alternatives to Animal Experiments (SAAE).

Dr. Michael Rothe is a lead scientist at the Hannover Medical School’s Institute of Experimental Hematology in Hannover, Germany. He is a biologist by training and focuses on the safety assessment of retroviral vectors that are used in gene therapy. Many inherited diseases can be treated with gene modification of hematopoietic stem cells, but in early clinical trials, several patients suffered from retroviral vector-induced leukemia. The risk for malignant mutagenesis due to gene insertion can be addressed by viral integration site analysis in animal models, but the predictive value of these studies is limited and the burden to the animal is not justified when an alternative exists. The In Vitro IMmortalization assay (IVIM), developed at the Hannover Medical School (MHH) in 2006, is a powerful in vitro test and has become a de facto gold standard assay for retroviral vector safety analysis and is considered a crucial element of an investigational new drug or clinical trial application by regulatory agencies (EMA, FDA, TGA, Health Canada). IVIM still has limitations associated with the use of myeloid cytokines and sensitivity. To overcome these limitations, Dr. Rothe and his team has developed the Surrogate Assay for Genotoxicity Assessment (SAGA). SAGA determines the risk of vector mutagenicity based on machine learning techniques applied to gene expression data. Currently, Dr. Rothe is working on an all-in-one safety test that detects insertional mutants, also from the lymphoid lineage. This work is conducted within the framework of the R2N ( – Replace and Reduce in Lower Saxony, Germany), a consortium devoted to developing alternative methods to replace and reduce animal models in biomedical research.